Safety and Efficacy Study of Epcoritamab in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

Estado	**Tipo de Participantes**	**Rangos de Edad**
Fin Reclutamiento	No aportado	Mayores de 64 , Adultos (18-64 años)
Género	**Fases**	**Participantes esperados**
Ambos	Fase I , Fase II	78
Resultados	**Bajo nivel intervención**	**Enfermedad rara**
Sin resultados	No	No
Cobertura geográfica	**Ámbitos del ensayo**	**Terapia avanzada**
Sin determinar	seguridad, eficacia, farmacocinética, farmacodinamica	NO

Información

Identificador

2023-504828-25-00 (CTIS)

Cod. Protocolo

GCT3013-03

Transicionado 2020-000848-57

Área terapéutica

Enfermedades [C] - Cáncer [C04]|

Enfermedad investigada

Chronic Lymphocytic Leukemia

Título Científico

A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

Justificación

No aportado

Objetivo Principal

Monotherapy Cohorts (R/R CLL)
Identify the RP2D and the MTD of epcoritamab
Evaluate the safety and tolerability of epcoritamab Expansion Monotherapy (R/R CLL [Arm 1] and RS [Arm 2A]):
Assess the preliminary efficacy of epcoritamab
Dose Escalation Venetoclax Combination Therapy (R/R CLL)
Identify the RP2D and the MTD of epcoritamab when coadministered with venetoclax 400 mg
Evaluate safety and tolerability of the combination of epcoritamab and venetoclax
Expansion Venetoclax Combination Therapy in R/R CLL (Arm 3)
Assess the preliminary antitumor effect of epcoritamab in combination with venetoclax
Expansion Lenalidomide Combination Therapy in RS (Arm 2B) and R CHOP Combination Therapy in RS (Arm 2C)
Assess the preliminary anti tumor effect of epcoritamab in combination with lenalidomide or R-CHOP

Variables de Evaluación Primaria

Monotherapy Cohorts (R/R CLL) Incidence of DLTs Incidence and severity of AEs and SAEs. Incidence and severity of CRS, ICANS and TLS
Monotherapy (R/R CLL [Arm 1 and 1A] and RS [Arm 2A]): ORR
Dose Escalation Venetoclax Combination Therapy (R/R CLL) Incidence of DLTs Incidence and severity of AEs
Expansion Venetoclax Combination Therapy in R/R CLL (Arm 3) ORR as assessed by the IRC
Expansion Lenalidomide Combination Therapy in RS (Arm 2B) and R CHOP Combination Therapy in RS (Arm 2C) ORR as assessed by the IRC

Momentos temporales de evaluación primaria

No aportado

Objetivo Secundario

Characterize the pharmacokinetic properties of epcoritamab
Evaluate immunogenicity of epcoritamab
Evaluate safety and tolerability of epcoritamab
Assess the preliminary anti-tumor activity of epcoritamab
Assess MRD in blood and marrow

Variables de Evaluación Secundaria

Monotherapy (R/R CLL [Arm 1] and RS [Arm 2A]), Expansion Lenalidomide Combination Therapy in RS (Arm 2B) and R CHOP Combination Therapy in RS (Arm 2C): DOR CR rate (both cohorts)/CRi rate (CLL cohort only) PR/nPR

rate TTR PFS OS TTNT Incidence and severity of AEs and SAEs. Incidence and severity of CRS, ICANS, and CTLS PK parameters Incidence of overall MRD negativity Duration of MRD negativity Incidence of ADAs to epcoritamab
Dose Escalation Venetoclax Combination Therapy (R/R CLL) ORR DOR CR/CRi rate TTR PFS OS TTNT PK parameters Incidence of overall MRD negativity Duration of MRD negativity Incidence of ADAs to epcoritamab
Safety Run-in Pirtobrutinib Combination Therapy (R/R CLL Cohort CP1) ORR DOR CR/CRi rate TTR PFS OS TTNT PK parameters Incidence of overall MRD negativity Incidence of MRD negativity 3 months after Day 1 of last cycle Duration of MRD negativity Incidence of ADAs to epcoritamab
Expansion Pirtobrutinib Combination Therapy in R/R CLL (Arm 4) ORR DOR CR/CRi rate TTR PFS OS TTNT Incidence and severity of AEs and SAEs Incidence and severity of CRS, ICANS, and CTLS PK parameters Incidence of overall MRD negativity Incidence of MRD negativity 3 months after Day 1 of last cycle Duration of MRD negativity Incidence of ADAs to epcoritamab

Momentos temporales de evaluación secundaria

No aportado

Criterios de Inclusión

All Subjects Subject must sign an ICF, prior to any Screening procedures Must be at least 18 years of age ECOG performance status score of 0,1 or 2 Evidence of CD20 positivity in a sample representative of the disease (eg, tumor biopsy/peripheral blood/bone arrow) at Screening Has acceptable laboratory parameters A woman with reproductive potential must agree to use adequate contraception during the trial, and for 12 months after the last administration of epcoritamab. A woman of childbearing potential must have a negative serum (betahCG) pregnancy test at Screening and a negative serum or urine pregnancy test before treatment administration on Day 1 of every cycle. A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the entire trial, until 12 months after last treatment. A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control.
Inclusion Criteria Specific to Subjects With R/R CLL Dose Escalation Monotherapy (All Cohorts) and Expansion Monotherapy (Arm 1) Must have active CLL/SLL disease that needs treatment per iwCLL R/R CLL after receiving at least 2 prior lines of therapy. Diagnosis of CLL/SLL that meets published diagnostic criteria (Hallek et al., 2018a) Must take prophylaxis for TLS
Inclusion Criteria Specific to Subjects With Richter's Syndrome Expansion Monotherapy Arm 2A Must have measurable disease as determined by FDG- PET CT and a CT scan (or MRI) Must provide a mandatory FFPE tumor tissue sample;
Inclusion Criteria Specific to Subjects With Richter's Syndrome Lenalidomide Combination Therapy Expansion Arm 2B Have tumor biopsy-proven CD20+ DLBCL and a clinical history of CLL/SLL. Deemed as ineligible for chemoimmunotherapy Eligible for treatment with lenalidomide. Must have measurable disease as determined by FDG- PET CT and a CT scan (or MRI) Must provide a mandatory FFPE tumor tissue sample; Females of childbearing potential must use 2 forms of contraception A woman of childbearing potential must have a negative serum (betahCG) pregnancy test Males must always use a latex or synthetic condom during any sexual contact with females of reproductive potential while taking lenalidomide
Inclusion Criteria Specific to Subjects With Richter's Syndrome R-CHOP Combination Therapy Expansion Arm 2C Have tumor biopsy-proven CD20+ DLBCL and have a clinical history of CLL/SLL. Eligible to receive R-CHOP per investigator determination. Must have measurable disease as determined by FDG- PET CT and a CT scan (or MRI) Must provide a mandatory FFPE tumor tissue sample;
Inclusion Criteria Specific to Subjects with R/R CLL Venetoclax Combination Therapy Dose Escalation Cohorts and Expansion Arm 3 Must have active CLL/SLL disease that needs treatment per iwCLL
Inclusion Criteria Specific to Subjects with R/R CLL Pirtobrutinib Combination Therapy Safety Run-in CP cohorts and Expansion Arm 4: Must have active CLL/SLL disease that needs treatment with at least 1 of the criteria being met. Presence of measurable disease. Previous treatment with at least one and a maximum 3 prior lines of therapy and must include a covalent BTKi. Diagnosis of CLL/SLL that meets published iwCLL criteria at the time of diagnosis.

Females of childbearing potential must use highly effective contraceptive measures while taking pirtobrutinib and for 28 days after the last dose. A woman must agree not to breastfeed a child during treatment and until one week after last dose. A man who is sexually active with a woman of childbearing potential must use an effective method of contraception during treatment and for 3 months after last dose

Criterios de Exclusión

Subject received prior treatment with a CD3×CD20 bsAb. Subject has history or presence of clinically relevant disorder affecting the CNS ICE score of less than 8 at study entry Subject has known past or current malignancy other than inclusion diagnosis, except for: a. Cervical carcinoma of Stage 1B or less b. Non-invasive basal cell or squamous cell skin carcinoma c. Non-invasive, superficial bladder cancer d. Prostate cancer with a current PSA level <0.1 ng/mL e. Any curable cancer with a CR of >2 years duration Subject has suspected allergies, hypersensitivity, or intolerance to epcoritamab or another anti-CD20 mAb or its excipients (refer to the IB for more information). Active HBV (DNA PCR-positive). Subjects with evidence of prior HBV but who are PCR-negative are permitted in the trial but should receive prophylactic antiviral therapy. Any of the following active infections: - Hepatitis C (RNA PCR-positive infection). Subjects who received treatment for HCV that was intended to eradicate the virus may participate if hepatitis C RNA levels are undetectable. Known Human T cell leukemia virus infection -Active CMV infection Subject is a woman who is pregnant or breastfeeding, or who is planning to become pregnant while enrolled in this trial or within 12 months after the last dose of epcoritamab. Subject is a man who plans to father a child while enrolled in this trial or within 12 months after the last dose of epcoritamab Subject received any prior allogeneic HSCT or solid organ transplantation Subject received treatment with an anticancer agent, as follows: - Subject received treatment with an investigational drug, within 4 weeks or 5 half lives, whichever is shorter, prior to the first dose of epcoritamab. Subject has autoimmune disease or other diseases that require permanent or high-dose immunosuppressive therapy Uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia (requiring >20 mg of prednisolone daily) or other concurrent uncontrolled medical conditions. Unstable or uncontrolled disease/condition related to or affecting cardiac function, eg, unstable angina, congestive heart failure grade III or IV as classified by the New York Heart Association, uncontrolled clinically significant cardiac arrhythmia (CTCAE v5.0 grade 2 or higher), or clinically significant ECG abnormalities Myocardial infarction, intracranial bleed, or stroke within the past 6 months Subject age 75 and 2 or more active grade 2 cardiovascular conditions. Subject has toxicities from previous anticancer therapies that have not resolved to baseline levels or to grade 1 or less except for alopecia and peripheral neuropathy

Calendario

(Última actualización: 31/03/2026)

Autorización	Inicio de Ensayo	Inclusión Primer Paciente	Interrumpido	Reiniciado
01/03/2023	15/03/2023	23/06/2023	No aportado	No aportado

Fin de reclutamiento	Fin prematuro (España)	Fin prematuro (Global)	Fin del ensayo en España	Fin del ensayo global
02/02/2026	No aportado	No aportado	No aportado	No aportado

Promotor

Genmab A/S Denmark

Kalvebod Brygge 43

Contact Person

Trial Information

+4570202728

clinicaltrials@genmab.com

Monetary support: N/A

Tipo de promotor: Comercial

Ceim

CEIm Hospital Clinic de Barcelona

Villarroel, 170 - Planta 0 - Puerta 6b 08036 Barcelona

ceic@clinic.cat

932275766

Centros

Activo (06/07/2023)

HOSPITAL CLINIC DE BARCELONA

Barcelona

BARCELONA

Hematology

Activo (06/02/2024)

HOSPITAL CLINICO UNIVERSITARIO DE VALENCIA

València

VALENCIA

Hematology and Medical Oncology

Activo (17/01/2024)

HOSPITAL DE LA SANTA CREU I SANT PAU

Barcelona

BARCELONA

Hematology

No iniciado (--/--/----)

Hospital De La Santa Creu I Sant Pau

Barcelona

BARCELONA

Hematology

Activo (26/07/2023)

HOSPITAL UNIVERSITARIO FUNDACION JIMENEZ DIAZ

Madrid

MADRID

Oncology

Activo (29/03/2023)

HOSPITAL UNIVERSITARIO RAMON Y CAJAL

Madrid

MADRID

Hematology

No iniciado (--/--/----)

Hospital Universitario Virgen De La Macarena

Sevilla

SEVILLA

Hematology

Activo (25/03/2024)

Hospital Universitario Virgen Macarena

Sevilla

SEVILLA

No iniciado (--/--/----)

Institut Catala D´oncologia

Badalona

BARCELONA

Clinical Hematology

Activo (16/02/2024)

Institut Catala D'oncologia

Badalona

BARCELONA

Hematology

No iniciado (27/03/2023)

Institut Catala D'oncologia

Hospitalet de Llobregat, L'

BARCELONA

Hematology

Medicamentos

-
-
SOLUTION FOR INFUSION

Código ATC: L01FA01 - RITUXIMAB
Principios Activos: N/A

Experimental

Epcoritamab
SOLUTION FOR INJECTION
SUBCUTANEOUS

-
Principios Activos: N/A

Huérfano

Experimental

Epcoritamab
SOLUTION FOR INJECTION
SUBCUTANEOUS

-
Principios Activos: N/A

Huérfano

Experimental

-
-
ORAL USE

Código ATC: H02AB06 - PREDNISOLONA
Principios Activos: N/A

Experimental

Jaypirca 50 mg film-coated tablets
FILM-COATED TABLET
ORAL USE

-
Principios Activos: N/A

Experimental

-
-
SOLUTION FOR INFUSION

Código ATC: L01AA01 - CICLOFOSFAMIDA
Principios Activos: N/A

Experimental

-
-
ORAL

Código ATC: L04AX04 - LENALIDOMIDA
Principios Activos: N/A

Experimental

-
-
SOLUTION FOR INFUSION

Código ATC: L01CA02 - VINCRISTINA
Principios Activos: N/A

Experimental

Jaypirca 100 mg film-coated tablets
FILM-COATED TABLET
ORAL USE

-
Principios Activos: N/A
Huérfano
Experimental

-
-
SOLUTION FOR INFUSION

Código ATC: L01DB01 - DOXORUBICINA
Principios Activos: N/A
Experimental

-
-
ORAL

Código ATC: L01XX52 - VENETOCLAX
Principios Activos: N/A
Experimental

Sin resultados

Safety and Efficacy Study of Epcoritamab in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

State	Type of participants	Age Ranges
End of recruitment	Not provided	Older than 64 , Adults (18-64 years)
Gender	**Phases**	**Expected Participants**
Both	Phase I , Phase II	78
Results	**Low level of intervention**	**Rare disease**
No results	No	No
Geographic coverage	**Areas of the study**	**Advanced therapy**
Undetermined	safety, effectiveness, pharmacokinetics, pharmacodynamics	NO

Information

Identifier
2023-504828-25-00 (CTIS)

Protocol Code
GCT3013-03

Transitioned 2020-000848-57

Therapeutic area
Diseases [C] - Cancer [C04]|

Investigated Disease
Chronic Lymphocytic Leukemia

Scientific Title
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

Rationale

Not provided

Main Objective

Monotherapy Cohorts (R/R CLL)
Identify the RP2D and the MTD of epcoritamab
Evaluate the safety and tolerability of epcoritamab Expansion Monotherapy (R/R CLL [Arm 1] and RS [Arm 2A]):
Assess the preliminary efficacy of epcoritamab
Dose Escalation Venetoclax Combination Therapy (R/R CLL)
Identify the RP2D and the MTD of epcoritamab when coadministered with venetoclax 400 mg
Evaluate safety and tolerability of the combination of epcoritamab and venetoclax
Expansion Venetoclax Combination Therapy in R/R CLL (Arm 3)
Assess the preliminary antitumor effect of epcoritamab in combination with venetoclax
Expansion Lenalidomide Combination Therapy in RS (Arm 2B) and R CHOP Combination Therapy in RS (Arm 2C)
Assess the preliminary anti tumor effect of epcoritamab in combination with lenalidomide or R-CHOP

Primary Endpoints

Monotherapy Cohorts (R/R CLL) Incidence of DLTs Incidence and severity of AEs and SAEs. Incidence and severity of CRS, ICANS and TLS
Monotherapy (R/R CLL [Arm 1 and 1A] and RS [Arm 2A]): ORR
Dose Escalation Venetoclax Combination Therapy (R/R CLL) Incidence of DLTs Incidence and severity of AEs
Expansion Venetoclax Combination Therapy in R/R CLL (Arm 3) ORR as assessed by the IRC
Expansion Lenalidomide Combination Therapy in RS (Arm 2B) and R CHOP Combination Therapy in RS (Arm 2C) ORR as assessed by the IRC

Temporary moments of secondary assessment

Not provided

Secondary Objective

Characterize the pharmacokinetic properties of epcoritamab
Evaluate immunogenicity of epcoritamab
Evaluate safety and tolerability of epcoritamab
Assess the preliminary anti-tumor activity of epcoritamab
Assess MRD in blood and marrow

Secondary Endpoints

Monotherapy (R/R CLL [Arm 1] and RS [Arm 2A]), Expansion Lenalidomide Combination Therapy in RS (Arm 2B) and R CHOP Combination Therapy in RS (Arm 2C): DOR CR rate (both cohorts)/CRi rate (CLL cohort only) PR/nPR

rate TTR PFS OS TTNT Incidence and severity of AEs and SAEs. Incidence and severity of CRS, ICANS, and CTLS PK parameters Incidence of overall MRD negativity Duration of MRD negativity Incidence of ADAs to epcoritamab
Dose Escalation Venetoclax Combination Therapy (R/R CLL) ORR DOR CR/CRi rate TTR PFS OS TTNT PK parameters Incidence of overall MRD negativity Duration of MRD negativity Incidence of ADAs to epcoritamab
Safety Run-in Pirtobrutinib Combination Therapy (R/R CLL Cohort CP1) ORR DOR CR/CRi rate TTR PFS OS TTNT PK parameters Incidence of overall MRD negativity Incidence of MRD negativity 3 months after Day 1 of last cycle Duration of MRD negativity Incidence of ADAs to epcoritamab
Expansion Pirtobrutinib Combination Therapy in R/R CLL (Arm 4) ORR DOR CR/CRi rate TTR PFS OS TTNT Incidence and severity of AEs and SAEs Incidence and severity of CRS, ICANS, and CTLS PK parameters Incidence of overall MRD negativity Incidence of MRD negativity 3 months after Day 1 of last cycle Duration of MRD negativity Incidence of ADAs to epcoritamab

Temporary moments of secondary assessment

Not provided

Inclusion criteria

All Subjects Subject must sign an ICF, prior to any Screening procedures Must be at least 18 years of age ECOG performance status score of 0,1 or 2 Evidence of CD20 positivity in a sample representative of the disease (eg, tumor biopsy/peripheral blood/bone arrow) at Screening Has acceptable laboratory parameters A woman with reproductive potential must agree to use adequate contraception during the trial, and for 12 months after the last administration of epcoritamab. A woman of childbearing potential must have a negative serum (betahCG) pregnancy test at Screening and a negative serum or urine pregnancy test before treatment administration on Day 1 of every cycle. A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the entire trial, until 12 months after last treatment. A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control.
Inclusion Criteria Specific to Subjects With R/R CLL Dose Escalation Monotherapy (All Cohorts) and Expansion Monotherapy (Arm 1) Must have active CLL/SLL disease that needs treatment per iwCLL R/R CLL after receiving at least 2 prior lines of therapy. Diagnosis of CLL/SLL that meets published diagnostic criteria (Hallek et al., 2018a) Must take prophylaxis for TLS
Inclusion Criteria Specific to Subjects With Richter's Syndrome Expansion Monotherapy Arm 2A Must have measurable disease as determined by FDG- PET CT and a CT scan (or MRI) Must provide a mandatory FFPE tumor tissue sample;
Inclusion Criteria Specific to Subjects With Richter's Syndrome Lenalidomide Combination Therapy Expansion Arm 2B Have tumor biopsy-proven CD20+ DLBCL and a clinical history of CLL/SLL. Deemed as ineligible for chemoimmunotherapy Eligible for treatment with lenalidomide. Must have measurable disease as determined by FDG- PET CT and a CT scan (or MRI) Must provide a mandatory FFPE tumor tissue sample; Females of childbearing potential must use 2 forms of contraception A woman of childbearing potential must have a negative serum (betahCG) pregnancy test Males must always use a latex or synthetic condom during any sexual contact with females of reproductive potential while taking lenalidomide
Inclusion Criteria Specific to Subjects With Richter's Syndrome R-CHOP Combination Therapy Expansion Arm 2C Have tumor biopsy-proven CD20+ DLBCL and have a clinical history of CLL/SLL. Eligible to receive R-CHOP per investigator determination. Must have measurable disease as determined by FDG- PET CT and a CT scan (or MRI) Must provide a mandatory FFPE tumor tissue sample;
Inclusion Criteria Specific to Subjects with R/R CLL Venetoclax Combination Therapy Dose Escalation Cohorts and Expansion Arm 3 Must have active CLL/SLL disease that needs treatment per iwCLL
Inclusion Criteria Specific to Subjects with R/R CLL Pirtobrutinib Combination Therapy Safety Run-in CP cohorts and Expansion Arm 4: Must have active CLL/SLL disease that needs treatment with at least 1 of the criteria being met. Presence of measurable disease. Previous treatment with at least one and a maximum 3 prior lines of therapy and must include a covalent BTKi. Diagnosis of CLL/SLL that meets published iwCLL criteria at the time of diagnosis.

Females of childbearing potential must use highly effective contraceptive measures while taking pirtobrutinib and for 28 days after the last dose. A woman must agree not to breastfeed a child during treatment and until one week after last dose. A man who is sexually active with a woman of childbearing potential must use an effective method of contraception during treatment and for 3 months after last dose

Exclusion criteria

Subject received prior treatment with a CD3×CD20 bsAb. Subject has history or presence of clinically relevant disorder affecting the CNS ICE score of less than 8 at study entry Subject has known past or current malignancy other than inclusion diagnosis, except for: a. Cervical carcinoma of Stage 1B or less b. Non-invasive basal cell or squamous cell skin carcinoma c. Non-invasive, superficial bladder cancer d. Prostate cancer with a current PSA level <0.1 ng/mL e. Any curable cancer with a CR of >2 years duration Subject has suspected allergies, hypersensitivity, or intolerance to epcoritamab or another anti-CD20 mAb or its excipients (refer to the IB for more information). Active HBV (DNA PCR-positive). Subjects with evidence of prior HBV but who are PCR-negative are permitted in the trial but should receive prophylactic antiviral therapy. Any of the following active infections: - Hepatitis C (RNA PCR-positive infection). Subjects who received treatment for HCV that was intended to eradicate the virus may participate if hepatitis C RNA levels are undetectable. Known Human T cell leukemia virus infection -Active CMV infection Subject is a woman who is pregnant or breastfeeding, or who is planning to become pregnant while enrolled in this trial or within 12 months after the last dose of epcoritamab. Subject is a man who plans to father a child while enrolled in this trial or within 12 months after the last dose of epcoritamab Subject received any prior allogeneic HSCT or solid organ transplantation Subject received treatment with an anticancer agent, as follows: - Subject received treatment with an investigational drug, within 4 weeks or 5 half lives, whichever is shorter, prior to the first dose of epcoritamab. Subject has autoimmune disease or other diseases that require permanent or high-dose immunosuppressive therapy Uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia (requiring >20 mg of prednisolone daily) or other concurrent uncontrolled medical conditions. Unstable or uncontrolled disease/condition related to or affecting cardiac function, eg, unstable angina, congestive heart failure grade III or IV as classified by the New York Heart Association, uncontrolled clinically significant cardiac arrhythmia (CTCAE v5.0 grade 2 or higher), or clinically significant ECG abnormalities Myocardial infarction, intracranial bleed, or stroke within the past 6 months Subject age 75 and 2 or more active grade 2 cardiovascular conditions. Subject has toxicities from previous anticancer therapies that have not resolved to baseline levels or to grade 1 or less except for alopecia and peripheral neuropathy

Calendar

(Last Update: 31/03/2026)

Authorization	Start of Trial	First patient inclusion	Halted	Restarted
01/03/2023	15/03/2023	23/06/2023	Not aported	Not aported

End of recruitment	Premature end (Spain)	Premature End (Global)	Trial end (Spain)	Trial end (Global)
02/02/2026	Not aported	Not aported	Not aported	Not aported

Sponsor

Genmab A/S Denmark

Kalvebod Brygge 43

Contact Person

Trial Information

+4570202728

clinicaltrials@genmab.com

Monetary support: N/A

Sponsor type: Commercial

Ceim

CEIm Hospital Clinic de Barcelona

Villarroel, 170 - Planta 0 - Puerta 6b 08036 Barcelona

ceic@clinic.cat

932275766

Sites

Active (06/07/2023)

HOSPITAL CLINIC DE BARCELONA

Barcelona

BARCELONA

Hematology

Active (06/02/2024)

HOSPITAL CLINICO UNIVERSITARIO DE VALENCIA

València

VALENCIA

Hematology and Medical Oncology

Active (17/01/2024)

HOSPITAL DE LA SANTA CREU I SANT PAU

Barcelona

BARCELONA

Hematology

not initialized (--/--/----)

Hospital De La Santa Creu I Sant Pau

Barcelona

BARCELONA

Hematology

Active (26/07/2023)

HOSPITAL UNIVERSITARIO FUNDACION JIMENEZ DIAZ

Madrid

MADRID

Oncology

Active (29/03/2023)

HOSPITAL UNIVERSITARIO RAMON Y CAJAL

Madrid

MADRID

Hematology

not initialized (--/--/----)

Hospital Universitario Virgen De La Macarena

Sevilla

SEVILLA

Hematology

Active (25/03/2024)

Hospital Universitario Virgen Macarena

Sevilla

SEVILLA

not initialized (--/--/----)

Institut Catala D´oncologia

Badalona

BARCELONA

Clinical Hematology

Active (16/02/2024)

Institut Catala D'oncologia

Badalona

BARCELONA

Hematology

not initialized (27/03/2023)

Institut Catala D'oncologia

Hospitalet de Llobregat, L'

BARCELONA

Hematology

Medication

-
-
SOLUTION FOR INFUSION

ATC code: L01FA01 - RITUXIMAB
Active Principles: N/A

Experimental

Epcoritamab
SOLUTION FOR INJECTION
SUBCUTANEOUS

-
Active Principles: N/A

Orphan
Experimental

Epcoritamab
SOLUTION FOR INJECTION
SUBCUTANEOUS

-
Active Principles: N/A

Orphan
Experimental

-
-
ORAL USE

ATC code: H02AB06 - PREDNISOLONA
Active Principles: N/A

Experimental

Jaypirca 50 mg film-coated tablets
FILM-COATED TABLET
ORAL USE

-
Active Principles: N/A

Experimental

-
-
SOLUTION FOR INFUSION

ATC code: L01AA01 - CICLOFOSFAMIDA
Active Principles: N/A

Experimental

-
-
ORAL

ATC code: L04AX04 - LENALIDOMIDA
Active Principles: N/A

Experimental

-
-
SOLUTION FOR INFUSION

ATC code: L01CA02 - VINCRISTINA
Active Principles: N/A

Experimental

Jaypirca 100 mg film-coated tablets
FILM-COATED TABLET
ORAL USE

-

Active Principles: N/A

Orphan Experimental

-
-
SOLUTION FOR INFUSION

ATC code: L01DB01 - DOXORUBICINA
Active Principles: N/A

Experimental

-
-
ORAL

ATC code: L01XX52 - VENETOCLAX
Active Principles: N/A

Experimental

No results